BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23945238)

  • 1. Predicting time to ovarian carcinoma recurrence using protein markers.
    Yang JY; Yoshihara K; Tanaka K; Hatae M; Masuzaki H; Itamochi H; ; Takano M; Ushijima K; Tanyi JL; Coukos G; Lu Y; Mills GB; Verhaak RG
    J Clin Invest; 2013 Sep; 123(9):3740-50. PubMed ID: 23945238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer.
    Skirnisdottir I; Seidal T
    Cancer Genomics Proteomics; 2013; 10(1):27-34. PubMed ID: 23382584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
    Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
    Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
    Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
    Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
    [No Abstract]   [Full Text] [Related]  

  • 6. Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy.
    Nishimura S; Tsuda H; Kataoka F; Arao T; Nomura H; Chiyoda T; Susumu N; Nishio K; Aoki D
    Hum Pathol; 2011 Apr; 42(4):516-21. PubMed ID: 21237490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis.
    Tsofack SP; Meunier L; Sanchez L; Madore J; Provencher D; Mes-Masson AM; Lebel M
    BMC Cancer; 2013 Jun; 13():303. PubMed ID: 23800275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.
    Kim CY; Jeong SY; Chong GO; Son SH; Jung JH; Kim DH; Lee SW; Ahn BC; Lee J
    Gynecol Oncol; 2015 Mar; 136(3):498-504. PubMed ID: 25557270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KCNN4 and S100A14 act as predictors of recurrence in optimally debulked patients with serous ovarian cancer.
    Zhao H; Guo E; Hu T; Sun Q; Wu J; Lin X; Luo D; Sun C; Wang C; Zhou B; Li N; Xia M; Lu H; Meng L; Xu X; Hu J; Ma D; Chen G; Zhu T
    Oncotarget; 2016 Jul; 7(28):43924-43938. PubMed ID: 27270322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer.
    Liu M; Mor G; Cheng H; Xiang X; Hui P; Rutherford T; Yin G; Rimm DL; Holmberg J; Alvero A; Silasi DA
    Reprod Sci; 2013 May; 20(5):605-15. PubMed ID: 23171677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated expression of MAC30 predicts lymph node metastasis and unfavorable prognosis in patients with epithelial ovarian cancer.
    Yang S; Li H; Liu Y; Ning X; Meng F; Xiao M; Wang D; Lou G; Zhang Y
    Med Oncol; 2013 Mar; 30(1):324. PubMed ID: 23254963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CD133 and CD117 in 64 Serous Ovarian Cancer Cases.
    Stemberger-Papić S; Vrdoljak-Mozetic D; Ostojić DV; Rubesa-Mihaljević R; Krigtofić I; Brncić-Fisher A; Kragević M; Eminović S
    Coll Antropol; 2015 Sep; 39(3):745-53. PubMed ID: 26898076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of pathway-based recurrence-associated signatures in optimally debulked patients with serous ovarian cancer.
    Deng K; Zhang F; Song W; Zhao W; Rong Z; Cai Y; Xu H; Lu M; Wang W; Li A; Hou Y; Li Z; Li K
    J Cell Biochem; 2018 Nov; 119(10):8564-8573. PubMed ID: 30126000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
    Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
    Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear β-catenin positivity as a predictive marker of long-term survival in advanced epithelial ovarian cancer.
    Nagy B; Tóth L; Molnár P; Méhes G; Thurzó L; Póka R; Hernádi Z
    Pathol Res Pract; 2017 Aug; 213(8):915-921. PubMed ID: 28651933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of astrocyte elevated gene-1 expression in human epithelial ovarian carcinoma.
    Meng F; Luo C; Ma L; Hu Y; Lou G
    Int J Gynecol Pathol; 2011 Mar; 30(2):145-50. PubMed ID: 21293286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Over-expression of Sirt1 contributes to chemoresistance and indicates poor prognosis in serous epithelial ovarian cancer (EOC).
    Shuang T; Wang M; Zhou Y; Shi C
    Med Oncol; 2015 Dec; 32(12):260. PubMed ID: 26520143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.
    Paek J; Lee M; Nam EJ; Kim SW; Kim YT
    Arch Gynecol Obstet; 2016 Mar; 293(3):645-50. PubMed ID: 26305032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.